Register for our free email digests:
Endo Pharmaceuticals Inc.
Division of Endo International PLC
www.endo.com/endopharma/home
Latest From Endo Pharmaceuticals Inc.
Five Companies To Watch At The Jefferies Conference
Novartis and Roche will present alongside up-and-coming biotechs and microcaps.
.Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike
VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.
Endo’s Opana IR Should Not Add Pediatric Data To Labeling, US FDA Panel Says
Incorporating data from two studies that raised safety and efficacy concerns would give a false sense of security about the drug’s use in pediatric patients, the panel majority said, while dissenters said some pediatric data in labeling is better than no information at all.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Gynecological, Urological
- Metabolic Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
- Contact Info
-
Endo Pharmaceuticals Inc.
Phone: (484) 216-0000
1400 Atwater Dr.
Malvern, PA 19355
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice